Quad by MEDVi Review: Four Actives in One Dose — Which Is the Selling Point and the Problem

What Is Quad by MEDVi?

Quad is MEDVi's erectile dysfunction product: a compounded sublingual liquid you hold under the tongue rather than a swallowed tablet. MEDVi's own page describes four components — PT-141 for 'desire activation', L-citrulline for 'blood flow', sildenafil for 'peak strength' and tadalafil for '36-hour duration'. It is sold at $114/month against a stated $179 retail price, with a doctor consultation, free rush shipping and 24/7 medical support included, on cancel-anytime terms and with a 'if you don't qualify, you don't pay' guarantee.

The sublingual delivery claim is the most defensible part of the pitch. Absorption through the mucosa under the tongue does bypass first-pass metabolism and can produce a faster onset than an oral tablet. For a product where timing matters, that is a real advantage rather than marketing.

Everything after that requires scrutiny. No ingredient strengths are published anywhere on the page. Third-party coverage of Quad is also inconsistent with MEDVi's own description — several sites describe the formula as sildenafil, tadalafil, vardenafil and apomorphine, a materially different and in some ways more concerning combination. When independent write-ups cannot agree with the manufacturer's page on what is actually in a prescription product, that is itself a finding.

Quad also comes from a parent with a difficult record. MEDVi holds an F rating from the Better Business Bureau, which lists 682 complaints against the business with 100 unanswered, and the FDA issued MEDVi warning letter 721455 in February 2026. In fairness, that letter concerned MEDVi's compounded semaglutide and tirzepatide products, not this ED line — we cover it fully in our separate MEDVi review and do not claim it applies to Quad.

What's In It & What It Costs

Prices are as published on 6 August 2026. The critical gap in this table is not our reporting — it is MEDVi's. No strength is given for any of the four actives, so you cannot know how much sildenafil or tadalafil you are taking, which is basic information for any PDE5 inhibitor and essential if you take other medication. For comparison, Ro publishes generic sildenafil at $4 to $10 per dose and tadalafil at $8 to $44 by strength, with the milligrams stated. At $114/month Quad is not obviously cheap, and it is the only one of the two where you cannot tell what dose you are getting.

Regulatory Status and the Combination Itself

Quad is a compounded preparation, which means it is not FDA-approved and has not been reviewed for safety, efficacy or manufacturing quality. Notably, the Quad page we reviewed carried no FDA-approval disclaimer at all — MEDVi's GLP-1 pages do carry one, so its absence here is inconsistent rather than merely unfortunate, particularly for a company that received an FDA warning letter in February 2026 over claims implying approval.

The combination itself is the substance of our concern, and it deserves stating plainly. Sildenafil and tadalafil are both PDE5 inhibitors working through the same mechanism, and both lower blood pressure. Combining two of them in one dose is not an FDA-approved regimen and offers no established benefit over an adequate dose of one, while the hypotensive effects are additive. That matters enormously with nitrates — nitroglycerin, isosorbide, or amyl nitrite 'poppers' — where the combination can cause a catastrophic drop in blood pressure, and it matters with alpha-blockers and in anyone with cardiovascular disease.

PT-141, or bremelanotide, is the component most people will not recognise. It is FDA-approved, but only as Vyleesi, an autoinjector for acquired generalised hypoactive sexual desire disorder in premenopausal women. It is not approved for men, and it is not approved for erectile dysfunction. In its trials nausea affected roughly four in ten users, and it produces transient increases in blood pressure with reductions in heart rate — which is why its labelling cautions against use in uncontrolled hypertension or known cardiovascular disease. Repeated use has also been associated with focal hyperpigmentation.

Put those together and the pharmacology is internally inconsistent: two agents that lower blood pressure combined with one that raises it, in unstated proportions, in a product whose cardiovascular risk profile has never been formally studied. That is not a formulation we would take on trust, and it is the reason for this review's rating.

L-citrulline is the least concerning ingredient and also the least consequential. It is an amino acid precursor to nitric oxide, sold widely as a supplement, with modest evidence at best for erectile function.

The Consultation Process

Eligibility

• •Eligibility is determined by a US-licensed doctor from your online intake. MEDVi states you do not pay if you do not qualify.
• •States served are not published on the Quad page we reviewed.
• •PDE5 inhibitors are absolutely contraindicated with nitrates in any form — nitroglycerin, isosorbide mononitrate or dinitrate, and recreational amyl nitrite 'poppers'. The combination can cause a life-threatening fall in blood pressure. Because Quad contains two PDE5 inhibitors, this warning applies with more force, not less.
• •Caution and clinician judgement are required with alpha-blockers for prostate or blood pressure conditions, in significant cardiovascular disease, recent stroke or heart attack, uncontrolled hypertension or hypotension, and in anyone advised against sexual activity on cardiac grounds.
• •PT-141's approved labelling cautions against use in uncontrolled hypertension or known cardiovascular disease because it transiently raises blood pressure. Anyone with a cardiac history should treat a product containing it — alongside two blood-pressure-lowering agents — as requiring specialist input, not an online form.
• •Common PDE5 inhibitor side effects include headache, flushing, nasal congestion, indigestion, back or muscle ache and visual disturbance. Priapism — an erection lasting more than four hours — is a medical emergency requiring immediate care. Sudden vision or hearing loss requires stopping the medication and urgent assessment.
• •PT-141 commonly causes nausea, flushing and headache, and repeated use has been associated with focal skin hyperpigmentation.
• •Erectile dysfunction is frequently the first presenting sign of cardiovascular disease, diabetes or hormonal disorder. Anyone with new-onset ED should be properly assessed for those causes rather than only treated symptomatically — a compounded convenience product does not substitute for that workup.

Prescribers, Testing & Pharmacy

Delivery & Support

Free rush shipping is included in the monthly price.

• •Sublingual delivery genuinely produces faster onset than a swallowed tablet
• •Doctor consultation included in the price
• •Free rush shipping
• •24/7 medical support advertised
• •Cancel-anytime terms
• •No charge if you do not qualify
• •Single monthly price covering product and service

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Quad by MEDVi May Be Best For

• •We do not have a group we would confidently recommend this to on the current information
• •At most: men with no cardiovascular history, on no nitrates or alpha-blockers, who have discussed the specific milligram strengths with the prescribing doctor and understand PT-141 is being used outside its approved population
• •Anyone in that position should still compare against FDA-approved generics at a known dose before choosing a compounded four-active blend

Limitations

• •Two PDE5 inhibitors in one dose is the core issue. Sildenafil and tadalafil do the same thing by the same mechanism; combining them adds cardiovascular risk without an established benefit over an adequate dose of either. Every safety warning that applies to one applies more strongly to both together — most critically the absolute contraindication with nitrates, where the consequence is a potentially fatal drop in blood pressure.
• •Adding PT-141 makes the combination harder to justify rather than better. It is approved only for premenopausal women with low sexual desire, has never been approved for men or for erectile dysfunction, causes nausea in roughly 40% of users in its trials, and transiently raises blood pressure — the opposite direction to the other two actives. Nobody has studied what that combination does to blood pressure in a man with borderline cardiac risk, because this product has never been studied at all.
• •Not publishing the strengths is indefensible for a prescription product. You cannot assess an interaction, compare value, or tell a treating clinician what you are taking if the milligrams are secret. If you use Quad, get the exact formulation in writing and keep it with your medication list.
• •The missing FDA disclaimer is a compliance gap with a specific history behind it. MEDVi received an FDA warning letter in February 2026 for claims that implied FDA approval where none existed. Selling a compounded ED product on a page with no regulatory statement at all, months after that letter, is a poor look — even though the letter itself concerned the company's GLP-1 line rather than this one.
• •Skipping lab work matters more in ED than in most conditions. New erectile dysfunction is frequently the earliest sign of cardiovascular disease, diabetes or hypogonadism, and treating the symptom online without assessing the cause can delay a diagnosis that matters far more than the symptom. A questionnaire is not a workup.
• •On value, the comparison is unflattering. Ro publishes generic sildenafil from $4 a dose and generic tadalafil from $8, both FDA-approved with strengths stated. Ten 100mg sildenafil doses a month costs roughly the same as Quad — for an approved medicine, at a dose you can name, with no unapproved peptide attached.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

The one genuinely good idea here is the delivery route. A sublingual liquid does absorb faster than a swallowed tablet, and for this category speed of onset is a real benefit rather than a marketing flourish. Bundling the consultation, rush shipping and support into a single $114 monthly price is also clean, and not charging men who do not qualify is the right policy.

The formulation is where it falls apart. Quad puts two PDE5 inhibitors — sildenafil and tadalafil — into one dose, which is not an approved regimen, adds no established benefit over an adequate dose of either, and makes their shared blood-pressure-lowering effect additive. It then adds PT-141, a peptide approved only for premenopausal women, never approved for men or for ED, which causes nausea in around 40% of trial users and pushes blood pressure in the opposite direction. None of the four strengths is published. Nobody has studied the combination, because compounded products are not studied.

The context does not help. The product page carries no FDA disclaimer, from a company the FDA wrote to in February 2026 about claims implying approval — a letter that concerned its GLP-1 line rather than this one, but which tells you how the company markets. MEDVi's BBB file records 682 complaints with 100 unanswered, dominated by billing and cancellation.

We rate Quad by MEDVi 1.7 out of 5. This is the lowest rating we have given a product in this roundup, and it is about the medicine rather than the company: an unstudied four-active blend containing an unapproved-for-men peptide, sold without dose disclosure, for a condition that often signals underlying cardiovascular disease and warrants proper assessment.

If you want ED treatment online, Ro publishes FDA-approved generic sildenafil from $4 a dose and tadalafil from $8, with the milligrams stated — roughly comparable monthly spend for a known drug at a known dose. If you have any cardiac history, take nitrates or alpha-blockers, or have new-onset symptoms, see a clinician in person before buying anything.

This review is informational only and is not medical advice. Compounded medications are not FDA-approved and have not been evaluated for safety, efficacy or quality. PDE5 inhibitors can interact dangerously with nitrates and other medicines. Speak to a licensed clinician about whether treatment is appropriate for you before starting, changing or stopping anything.